Stockscreener 앱 받기
1.32
0.76%
0.01
전일 마감가:
$1.31
열려 있는:
$1.3
하루 거래량:
1.41M
Relative Volume:
1.03
시가총액:
$95.44M
수익:
-
순이익/손실:
$-44.95M
주가수익비율:
-1.479
EPS:
-0.8925
순현금흐름:
$-56.37M
1주 성능:
-6.38%
1개월 성능:
+14.78%
6개월 성능:
-7.04%
1년 성능:
-31.61%
1일 변동 폭
$1.20
$1.33
1주일 범위
$1.20
$1.46
52주 변동 폭
$0.8719
$2.99
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.32 | 95.44M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting - Traders Union
Biomea Fusion Inc Financial Disclosures & SEC Filings - TradingView
Price to earnings forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to sales forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Price to book forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to revenue forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Insiders Buying Biomea Fusion Might Wish They Invested More, Stock Gains 12% - simplywall.st
Enterprise value to EBITDA forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Enterprise value to EBIT forward of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Inc Actuals & Estimates (NASDAQ:BMEA) - TradingView
COVALENT-112 Phase II data boost momentum for ico, Biomea Fusion pushes first-in-class strategy - Traders Union
BMEA Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Biomea Fusion forges new industry ties at BIO International Convention - Traders Union
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Team Fusion pinpoints this year leading trends at ADA2026 event - Traders Union
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Number of shareholders of Biomea Fusion, Inc. – NASDAQ:BMEA - TradingView
Biomea Fusion Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineOne-Time Gain Impact - newsline.com
Biomea Fusion Inc. Q1 2026 Earnings: EPS Beat on Cost Discipline as Biotech Advances PipelinePost-Announcement Reaction - newsline.com
[Form 4] Biomea Fusion, Inc. Insider Trading Activity - Stock Titan
Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price - Stock Titan
Biomea Fusion (BMEA) director Ray Sumita granted 196,299 stock options - Stock Titan
Biomea Fusion (BMEA) director receives 173,711-share stock option grant at $1.15 - Stock Titan
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion (NASDAQ: BMEA) details 2026 director and auditor votes - Stock Titan
BMEA: Directors and auditors were approved by majority vote, with results to be filed with the SEC - TradingView
BMEA: All proposals, including director elections and auditor ratification, were approved - TradingView
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Biomea Fusion, Inc. (BMEA) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow - Seeking Alpha
BMEA Q1 2026 Earnings: EPS Beat on Controlled Spending Overshadowed by Pipeline ConcernsAnalyst Drop Coverage - newsline.com
Biomea Fusion unveils new icovamenib data showing durable insulin secretion gains in T1D and T2D - Traders Union
Biomea Fusion shows promising diabetes and obesity drug data, expands Phase I study for weight loss therapy. - Pluang
Biomea Fusion Presents Promising Clinical Data for Icovamenib and Expands Phase I Study of BMF-650 at ADA 2026 - Quiver Quantitative
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association ('ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - The Manila Times
Biomea Fusion Says Icovamenib Data Show Muscle Preservation And Fat Reduction In Obesity And Diabetes - TradingView
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study - GlobeNewswire
BMEA: Phase II diabetes trials for a novel menin inhibitor target non-chronic, restorative therapy - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biomea Fusion to study icovamenib with semaglutide for weight loss - Investing.com UK
Icovamenib GLP-1 therapy combination evaluated in Biomea Fusion academic study - Traders Union
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity - Investing News Network
Biomea Fusion to study icovamenib with semaglutide for weight loss By Investing.com - Investing.com South Africa
Biomea Fusion Announces Research Collaboration with - GlobeNewswire
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):